The retail pharmacies will be in one company and Aetna and CVS Caremark, the PBM, in another, according to news reports.
News|Articles|October 29, 2012
Discontinuation of warfarin therapy higher than generally anticipated
Among older adults with atrial fibrillation (AF), persistence with warfarin therapy is generally lower than what has been reported in clinical trials, according study online in Archives of Internal Medicine.
Advertisement
Advertisement
Related to this article
Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Bronchiectasis 101: Why permanently dilated airways drive recurrent exacerbations
2
CVS Health is splitting in two, according to news reports
3
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
4
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
5